Stockscreener 앱 받기
8.16
2.28%
-0.19
시장 영업 전:
8.19
0.03
+0.37%
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Hedge Fund Moves: Is Fulcrum Therapeutics Inc part of any ETFJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
FULC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - Bitget
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 7.5%Here's Why - MarketBeat
FULC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Winners Losers: Can Fulcrum Therapeutics Inc keep up with sector leadersBond Market & Stepwise Swing Trade Plans - baoquankhu1.vn
Fulcrum: Strong HbF Signal, Narrow TAM, Same 'Hold' Conclusion (NASDAQ:FULC) - Seeking Alpha
Fulcrum Therapeutics, Inc. (FULC): Analyst Ratings Suggest 111% Upside Potential – Is It Time to Buy? - DirectorsTalk Interviews
HC Wainwright Has Optimistic Outlook of FULC Q1 Earnings - MarketBeat
FY2030 Earnings Forecast for FULC Issued By HC Wainwright - Defense World
Fulcrum Therapeutics move lower ‘overdone,’ says Stifel - Yahoo Finance
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright Maintains Buy on FULC Fulcrum Therapeutics, Inc. Feb 24, 2026 - Meyka
Earnings call transcript: Fulcrum Therapeutics Q4 2025 reports progress in sickle cell treatment - Investing.com Australia
Fulcrum Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Fulcrum Therapeutics stock falls as sickle cell trial misses target - Investing.com Australia
Fulcrum Therapeutics stock falls as sickle cell trial misses target By Investing.com - Investing.com Canada
Leerink reiterates Fulcrum Therapeutics stock rating on SCD data By Investing.com - Investing.com Canada
Fulcrum Therapeutics shares fall on profit-taking, Oppenheimer says By Investing.com - Investing.com Canada
BofA reiterates Fulcrum Therapeutics stock Underperform rating at $7 By Investing.com - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Shares Gap DownWhat's Next? - MarketBeat
Fulcrum Therapeutics Shares Surge on Promising Clinical Trial Data and Strong Financial Runway - NewsCase
Positive Developments in Fulcrum Therapeutics (FULC) Boost Inves - GuruFocus
Fulcrum Therapeutics Q4 Earnings Call Highlights - MarketBeat
Fulcrum Therapeutics (FULC) Shares Experience Unexpected Decline - GuruFocus
Fulcrum Therapeutics (FULC) Surpasses Expectations with Phase Ib Study Results - GuruFocus
FULC: Pociredir at 20 mg achieved strong HbF induction and clinical benefit in severe sickle cell disease - TradingView
What's Going On With Fulcrum Therapeutics Stock Tuesday? - Benzinga
Fulcrum Therapeutics Says Phase 1b Pociredir Trial Demonstrates Improvement in Sickle Cell Disease Therapy - marketscreener.com
Fulcrum Therapeutics (NASDAQ:FULC) Releases Quarterly Earnings Results, Meets Expectations - MarketBeat
Fulcrum Therapeutics (FULC) Reports Promising PIONEER Trial Resu - GuruFocus
Fulcrum Therapeutics stock tumbles despite trial results By Investing.com - Investing.com Canada
Biopharmaceutical company Fulcrum Therapeutics recently disclosed that by the end of 2025, its total holdings of cash, cash equivalents, and marketable securities will reach $352.3 million. - Bitget
Fulcrum Therapeutics stock tumbles despite trial results - Investing.com Australia
FULCRUM THERAPEUTICS ($FULC) Releases Q4 2025 Earnings - Quiver Quantitative
Fulcrum Therapeutics, Inc. SEC 10-K Report - TradingView
Fulcrum Therapeutics announces positive results from 20 mg dose cohort of phase 1b pioneer trial of Pociredir - marketscreener.com
Fulcrum Therapeutics (NASDAQ: FULC) posts wider 2025 loss and boosts cash runway - Stock Titan
Fulcrum Therapeutics Announces Recent Business Highlights - GlobeNewswire
Experimental sickle cell pill left most patients crisis-free for 12 weeks - Stock Titan
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025 - Bitget
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - Bitget
Aberdeen Group plc Acquires 79,265 Shares of Fulcrum Therapeutics, Inc. $FULC - Defense World
Will Fulcrum Therapeutics Inc. stock benefit from infrastructure spending2025 Pullback Review & Low Drawdown Momentum Trade Ideas - mfd.ru
Fulcrum Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Why Fulcrum Therapeutics Inc. stock attracts high net worth investorsEarnings Recap Report & Reliable Volume Spike Alerts - mfd.ru
Fulcrum Therapeutics (NASDAQ:FULC) Trading 6.5% HigherWhat's Next? - MarketBeat
Fulcrum Therapeutics, Inc. (FULC) Stock Analysis: Unpacking The 74.59% Potential Upside - DirectorsTalk Interviews
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease - The Manila Times
Fulcrum Therapeutics (FULC) to Release Quarterly Earnings on Tuesday - MarketBeat
Is Fulcrum Therapeutics Inc. stock a contrarian buyPortfolio Risk Report & Fast Gain Stock Tips - mfd.ru
Can Fulcrum Therapeutics Inc. stock deliver surprise earnings beatCPI Data & Verified Entry Point Detection - mfd.ru
Will Fulcrum Therapeutics Inc. stock benefit from automation2025 Winners & Losers & Low Risk High Win Rate Picks - mfd.ru
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: High-Growth - openPR.com
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
3.69%
0.68%
자본화:
|
볼륨(24시간):